SCHEMBL29892829

SCHEMBL29892829

Nc1ccc(Br)nc1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193404 1.00
SCHEMBL9903875 0.78
SCHEMBL30051908 0.78
SCHEMBL17255937 0.78 IMPDH2 (0.34)
SCHEMBL474806 0.78
SCHEMBL13191537 0.76
SCHEMBL23629644 0.74
SCHEMBL10197516 0.74
SCHEMBL857644 0.74
SCHEMBL17187244 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115160316-B Orange-red photo-thermal activation delay fluorescent material and synthesis method thereof 苏州大学 2024-03-19 CN claimed
CN-115160316-A Orange red photo-thermal activation delayed fluorescent material and synthetic method thereof 苏州大学 2022-10-11 CN claimed
WO-2025106949-A1 WRN INHIBITORS RADD PHARMACEUTICALS, INC. (US) 2025-05-22 WO disclosed
US-20250082633-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC (US) 2025-03-13 US disclosed
CN-119241532-A 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof 深圳市塔吉瑞生物医药有限公司 2025-01-03 CN disclosed
CN-118804912-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-10-18 CN disclosed
EP-4436961-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-10-02 EP disclosed
EP-4419532-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-08-28 EP disclosed
US-20240279237-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-08-22 US disclosed
CN-116323566-B Sulfanone compound and preparation method and medical application thereof 中国医药研究开发中心有限公司 2024-05-17 CN disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 WO disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
WO-2023097007-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-06-01 WO disclosed
CN-116057045-A Fibroblast growth factor receptor kinase inhibitors 金耐特生物制药公司 2023-05-02 CN disclosed
WO-2023066825-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-27 WO disclosed
CN-115894353-A Synthetic method of 2, 3-diamino-4-bromopyridine 山西永津集团有限公司 2023-04-04 CN disclosed
EP-4096668-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-115295736-A High-efficiency orange-red electroluminescent device 苏州大学 2022-11-04 CN disclosed
CN-115160316-A Orange red photo-thermal activation delayed fluorescent material and synthetic method thereof 苏州大学 2022-10-11 CN disclosed
WO-2022204452-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-09-29 WO disclosed